Treatment options for acromegaly

• Published in: Metabolism, clinical and experimental Vol. 45; no. 8 Suppl 1; pp. 63 - 64
• Main Authors: Sheppard, M.C., Stewart, P.M.
• Format: Journal Article
• Language: English
• Published: United States Elsevier Inc 01.08.1996
• Subjects: Acromegaly - drug therapy; Acromegaly - metabolism; Acromegaly - surgery; Growth Hormone - metabolism; Humans; Octreotide - administration & dosage; Octreotide - adverse effects; Octreotide - therapeutic use; Treatment Outcome
• ISSN: 0026-0495; 1532-8600
• DOI: 10.1016/S0026-0495(96)90085-2

Treatment options for acromegaly include surgical removal of the adenoma, radiotherapy, or pharmacological reduction of growth hormone (GH) levels by dopamine agonists or somatostatin analogs. Whether such treatment can truly cure acromegaly is debatable. A problem with evaluating efficacy of treatment is the lack of consensus of what constitutes a cure. Despite modern neurosurgical techniques for resecting GH-secreting pituitary adenomas, more than 50% of patients may have persistent GH hypersecretion; radiotherapy may take years to produce an effect. There is thus interest in pharmacological relief of symptoms and reduction in GH secretion. We report on eight patients with a biochemical diagnosis of acromegaly (failure of suppression of GH levels to < 2.5 μg/L following a glucose tolerance test [GTT]). The use of Sandostatin-LAR ® (Sandoz Pharma Ltd, Basel, Switzerland) in doses of 20 to 30 mg intramuscularly at 4 week intervals produced consistent and therapeutic serum octreotide concentrations, suppressed GH secretion to 5 μg/L in all eight subjects, lowered insulin-like growth factor-1 (IGF-1) levels in all and normalized values in seven of eight, improved or led to disappearance of symptoms and signs, and was not associated with an increase in adverse events as compared with subcutaneous treatment.